SwedenSweden

Backing for PIGF-blocker

14.08.2008

Lund/Leuven/Basel – Swedish drug development company BioInvent International AB and drug development partner Belgian ThromboGenics NV have entered into a multimillion-euro licensing agreement with Swiss pharma giant Roche. The strategic alliance encompasses the jointly developed anti-cancer agent TB-403, a humanised monoclonal antibody that blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels. TB-403 (Anti-PIGF) has completed its Phase I clinical trial, and recently received approval to enter a Phase Ib dose-escalation trial. TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB) at the University of Leuven (Belgium), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed.
The companies announced in June that BioInvent and ThromboGenics will receive EUR50m in an upfront payment from Roche. In addition, the Swedish and Belgian firms could potentially receive up to a450m over the term of the collaboration. Payments are dependent on the successful completion of a series of development and commercial milestones for multiple indications, as well as royalties on potential product sales, including any backup antibodies based on the inhibition of PIGF. ThromboGenics will receive 60% of the revenue from the deal, while BioInvent will take home 40%. Both firms retain the promotion rights for the antibody in the Nordic, Baltic and Bene-

lux regions. Roche receives a worldwide exclusive license to develop and commercialise the product, and assumes responsibility for all future development costs.

Roche will also provide the two companies with funding for research on non-cancer indications.

SwedenSweden

17.11.2011

Exton/Helsingborg – A Swedish specialist for improving glucocorticoid replacement therapy has attracted transatlantic attention. DuoCort Pharma AB, based in Helsingborg, was bought by ViroPharma Incorporated, an US-based...

SwedenSweden

01.10.2011

Uppsala/Basel – Swedish life science initiative Uppsala BIO is set to team up with drugmaker Hoffman-La Roche AG. For the next three years, the cluster will become the ninth member – and the first from Europe – of the Swiss...

SwedenSweden

01.10.2011

Uppsala – Backed by strong clinical research, the development of Orexo AB’s drug candidate OX219 for treatment of opioid dependence is gathering momentum. A clinical Phase I study was carried out to decide the commercial...

SwedenSweden

20.08.2011

Petach Tikva/Lund – Active Biotech AB suffered a severe setback in the development of its oral multiple sclerosis drug laquinimod. Together with ally Teva (Israel), the Swedish drugmaker announced that the substance failed in...

SwedenSweden

08.08.2011

Lund - Researchers from Lund University may have found a viable alternative to animal testing. In an article in the open access journal BMC Genomics (August 2011) they demonstrated that the response of laboratory grown human...

SwedenSweden

04.08.2011

Uppsala - After good interim results Oasmia wastes no time and starts the approval process for its ovarian cancer drug Paclical. The interim analysis, based on data from approximately 400 patients, showed the expected efficacy of...

SwedenSweden

02.08.2011

Petach Tikva/Lund - Active Biotech's experimental multiple sclerosis drug laquinimod failed in a phase III-trial. This is a major setback for the Swedish drug maker and its ally Teva Pharmaceutical Industries from Israel. Both...

SwedenSweden

30.06.2011

Huddinge, Sweden - Medivir cashes in on Medivir. For EUR 31m the Swedishspecialty pharma company sold all North American remaining rights forXerese, a drug against cold sores (herpes labialis), to Swedish Meda. InFebruary 2010,...

SwedenSweden

15.06.2011

Uppsala/Tokyo – Orexo AB’s cancer pain treatment Abstral has reached the Canadian drug market. The Swedish drugmaker confirmed yesterday that Paladin Labs Inc have launched marketing of the sublingual formulation of fentanyl in...

SwedenSweden

12.06.2011

Stockholm – Swedish investor Karolinska Development AB outperformed its own expectations in its Initial Public Offering on the Nasdaq OMX Stockholm. The company sold 15.2 million shares at SEK40 during the offering, raising a...

Displaying results 11 to 20 out of 182

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/1/article/backing-for-pigf-blocker.html

Product of the week

Products

Events

All Events

Current issue

All issues